Great Point Partners LLC Has $24.52 Million Holdings in ABIVAX Société Anonyme (NASDAQ:ABVX)

Great Point Partners LLC trimmed its position in ABIVAX Société Anonyme (NASDAQ:ABVX) by 13.9% during the 3rd quarter, Holdings Channel.com reports. The firm owned 2,128,773 shares of the company’s stock after selling 343,415 shares during the period. ABIVAX Société Anonyme comprises 7.2% of Great Point Partners LLC’s investment portfolio, making the stock its 2nd largest position. Great Point Partners LLC’s holdings in ABIVAX Société Anonyme were worth $24,523,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Kennedy Capital Management LLC increased its position in ABIVAX Société Anonyme by 35.3% during the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock valued at $1,718,000 after buying an additional 31,331 shares in the last quarter. Janus Henderson Group PLC boosted its stake in ABIVAX Société Anonyme by 18.2% in the 1st quarter. Janus Henderson Group PLC now owns 851,839 shares of the company’s stock worth $12,113,000 after purchasing an additional 131,414 shares in the last quarter. abrdn plc grew its position in ABIVAX Société Anonyme by 167.7% during the 3rd quarter. abrdn plc now owns 316,431 shares of the company’s stock valued at $3,645,000 after purchasing an additional 198,225 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in ABIVAX Société Anonyme by 82.6% in the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after buying an additional 5,900 shares during the last quarter. Hedge funds and other institutional investors own 47.91% of the company’s stock.

ABIVAX Société Anonyme Price Performance

Shares of ABVX opened at $8.50 on Wednesday. ABIVAX Société Anonyme has a twelve month low of $8.23 and a twelve month high of $17.02. The firm has a 50 day moving average of $10.23 and a 200 day moving average of $11.86.

ABIVAX Société Anonyme Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.